AbbVie
ABBV
$144.84
Share price
-1.20%
Change (1 day)
4.49%
Change (1 year)
Categories
The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol “ABBV”.
Operating Margin for AbbVie (ABBV)
Operating Margin as of February 2023 (TTM): 25.56%
According to AbbVie's latest financial reports and stock price the company's current Operating Margin is 25.56%. At the end of 2021 the company had an Operating Margin of 23.11%.
Operating Margin history for AbbVie from 2011 to 2022
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2021 | 23.11% | 211.56% |
| 2020 | 7.42% | -70.71% |
| 2019 | 25.33% | 59.63% |
| 2018 | 15.87% | -42.06% |
| 2017 | 27.39% | -10.95% |
| 2016 | 30.75% | 5.79% |
| 2015 | 29.07% | 144.93% |
| 2014 | 11.87% | -58.17% |
| 2013 | 28.38% | -8.9% |
| 2012 | 31.15% | 48.11% |
| 2011 | 21.03% | -31.99% |
| 2010 | 30.92% | -26.13% |
| 2009 | 41.86% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | 29.90% | -99.90% | 🇺🇸 USA |
 Eli Lilly LLY | 22.40% | -99.58% | 🇺🇸 USA |
 Amgen AMGN | 29.35% | -99.80% | 🇺🇸 USA |
 Biogen BIIB | 32.74% | -99.84% | 🇺🇸 USA |
 Gilead Sciences GILD | 16.73% | -99.85% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | 16.50% | -99.87% | 🇺🇸 USA |
 AstraZeneca AZN | -0.70% | -99.83% | 🇬🇧 UK |
 GlaxoSmithKline GSK | 15.36% | -99.93% | 🇬🇧 UK |
 Neurocrine Biosciences
NBIX | 8.94% | -99.71% | 🇺🇸 USA |
What is a company's Operating Margin
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.